Hepatic Encephalopathy (HE) Therapeutics Market (Updated Version Available)

HE is a potentially fatal brain disorder that is caused by liver damage, which results in the failure to remove toxins from the blood.
The availability of patient-focused programs to assist disease management is one of the primary growth drivers for the global hepatic encephalopathy (HE) therapeutics market till 2023. Such programs increase the adherence to therapeutics by improving convenience for patients. Norgine collaborated with the European liver patients association (ELPA) to launch Time to DeLiver program, which is focused on changing the perception about HE among all stakeholders, healthcare professionals, and policymakers. This in turn, drives the demand for diagnosis and management of HE.
The most commonly used therapeutics to treat HE are lactulose and rifaximin. Researchers are also developing treatments that targets ammonia production and removal. For instance, AST-120 is under investigation and targets gut-derived toxins for liver cirrhosis. It can also be used to treat HE. The progression and development of HE sometimes depends on factors such as inflammation. This is compelling researchers to introduce various treatments that targets inflammation. Some of the most recent approaches to treat HE includes probiotics, albumin administration, and dialysis. Such emergence of novel hepatic encephalopathy treatment targets is identified as one of the key trends that will stimulate growth in the hepatic encephalopathy (HE) therapeutics market during the forecasted period.
The report comprises of key players profiles namely consignment, price, revenue, profit interview records and sources of distribution. It helps clients get a better analysis of their competitors. In addition, it encompasses the regions and countries across the world and depicts the regional outlook, market size, volume, value and price data.
The Hepatic Encephalopathy (HE) Therapeutics market was valued at xxx million USD with a CAGR xx% from 2015-2019. Subsequently, it will touch xxx million USD in 2020 with a CAGR xx % from 2020 to 2025.
Global market, the following companies are covered:
ASKA Pharmaceutical
COSMO PHARMACEUTICALS
Mallinckrodt
Valeant


Market Segment by Product Type
Lactulose
Rifaximin
Neomycin
Probiotics
Thiamine

Market Segment by Application
Acute Liver Failure
Portal Systemic Bypass Without Liver Disease
Liver Cirrhosis

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The research provides answers to the following key questions:
• What is the estimated growth rate and market share and size of the Hepatic Encephalopathy (HE) Therapeutics market for the forecast period 2020 - 2025?
• What are the driving forces in the Hepatic Encephalopathy (HE) Therapeutics market for the forecast period 2020 - 2025?
• Who are the prominent market players and how have they gained a competitive edge over other competitors?
• What are the market trends influencing the progress of the Hepatic Encephalopathy (HE) Therapeutics industry worldwide?
• What are the major challenges and threats restricting the progress of the industry?
• What opportunities does the market hold for the prominent market players?